AKRO
Price
$28.89
Change
+$0.33 (+1.16%)
Updated
Dec 26, 04:59 PM (EDT)
77 days until earnings call
DNLI
Price
$21.34
Change
+$0.42 (+2.01%)
Updated
Dec 26, 04:59 PM (EDT)
67 days until earnings call
Ad is loading...

AKRO vs DNLI

Header iconAKRO vs DNLI Comparison
Open Charts AKRO vs DNLIBanner chart's image
Akero Therapeutics
Price$28.89
Change+$0.33 (+1.16%)
Volume$2.93K
CapitalizationN/A
Denali Therapeutics
Price$21.34
Change+$0.42 (+2.01%)
Volume$12.3K
CapitalizationN/A
AKRO vs DNLI Comparison Chart
Loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKRO vs. DNLI commentary
Dec 27, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Buy and DNLI is a Buy.

Ad is loading...
COMPARISON
Comparison
Dec 27, 2024
Stock price -- (AKRO: $28.56 vs. DNLI: $20.92)
Brand notoriety: AKRO and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 42% vs. DNLI: 30%
Market capitalization -- AKRO: $2.02B vs. DNLI: $3.07B
AKRO [@Biotechnology] is valued at $2.02B. DNLI’s [@Biotechnology] market capitalization is $3.07B. The market cap for tickers in the [@Biotechnology] industry ranges from $385.39B to $0. The average market capitalization across the [@Biotechnology] industry is $2.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • AKRO’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, AKRO is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 3 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • AKRO’s TA Score: 3 bullish, 4 bearish.
  • DNLI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both AKRO and DNLI are a bad buy in the short-term.

Price Growth

AKRO (@Biotechnology) experienced а -6.70% price change this week, while DNLI (@Biotechnology) price change was -9.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +6.71%. For the same industry, the average monthly price growth was +0.43%, and the average quarterly price growth was +6.36%.

Reported Earning Dates

AKRO is expected to report earnings on Mar 13, 2025.

DNLI is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (+6.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($3.07B) has a higher market cap than AKRO($2.02B). AKRO YTD gains are higher at: 22.313 vs. DNLI (-2.516). AKRO has higher annual earnings (EBITDA): -232.85M vs. DNLI (-496.05M). DNLI has more cash in the bank: 837M vs. AKRO (717M). AKRO has less debt than DNLI: AKRO (36.4M) vs DNLI (52.5M). AKRO (0) and DNLI (0) have equivalent revenues.
AKRODNLIAKRO / DNLI
Capitalization2.02B3.07B66%
EBITDA-232.85M-496.05M47%
Gain YTD22.313-2.516-887%
P/E RatioN/AN/A-
Revenue00-
Total Cash717M837M86%
Total Debt36.4M52.5M69%
FUNDAMENTALS RATINGS
DNLI: Fundamental Ratings
DNLI
OUTLOOK RATING
1..100
56
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
PROFIT vs RISK RATING
1..100
92
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
82
P/E GROWTH RATING
1..100
99
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
AKRODNLI
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
81%
Momentum
ODDS (%)
Bearish Trend 3 days ago
79%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
Advances
ODDS (%)
Bullish Trend 10 days ago
84%
Bullish Trend 18 days ago
79%
Declines
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
89%
Bullish Trend 3 days ago
68%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
View a ticker or compare two or three
Ad is loading...
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GCTRX48.310.57
+1.19%
Goldman Sachs US Tax-Managed Eq R6
TRACX17.030.14
+0.83%
PGIM Quant Solutions Small-Cap Val C
RSSRX26.830.21
+0.79%
Victory RS Select Growth R6
IFACX24.160.12
+0.50%
American Funds Income Fund of Amer C
NRIFX21.340.05
+0.23%
Nuveen Real Asset Income R6

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.67%
ETNB - AKRO
62%
Loosely correlated
-0.63%
BEAM - AKRO
44%
Loosely correlated
+0.38%
DNLI - AKRO
44%
Loosely correlated
+0.67%
PLRX - AKRO
43%
Loosely correlated
+1.12%
IDYA - AKRO
43%
Loosely correlated
-0.32%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.67%
BEAM - DNLI
64%
Loosely correlated
+0.38%
NTLA - DNLI
54%
Loosely correlated
-0.41%
LGND - DNLI
54%
Loosely correlated
-0.37%
CRSP - DNLI
52%
Loosely correlated
+1.14%
RCKT - DNLI
51%
Loosely correlated
+2.19%
More